Antibody Information
General Information of This Antibody (ID: ANTI0MXGYS)
| Antibody Name | Anti-SEZ6 antibody |
|||||
|---|---|---|---|---|---|---|
| Antigen Name | SEZ6 |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
Turmetabart adizutecan [Phase 3]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
21%
|
|||
| Patients Enrolled |
Eligible participants have ECOG 0-1, adequate organ function, QTc ≤450/470 msec (M/F), and measurable disease (RECIST 1.1/RANO). Parts 1-4 include R/R SCLC/CNS tumors/NECs progressing after SOC. Exclusions: ILD/pneumonitis, prior Top1-ADC therapy, or (Part 2) prior SEZ6-ADC. Fresh/archival tumor tissue is required for SEZ6 analysis.
|
||||
| Administration Dosage |
ABBV-706 was administered IV at 1.3-3.5 mg/kg doses Q3W in 21-d cycles.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05599984 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors
|
||||
| Primary Endpoint |
Primary outcomes include AE incidence, PK parameters (Cmax, Tmax, t½, AUC), immunogenicity (ADA/nAb incidence), and tumor response metrics (ORR per RECIST 1.1/RANO, DOR, PFS, OS) assessed over ~2 years. The RP2D will be determined based on safety, PK, and efficacy data.
|
||||
References